Shire To Pay $75 Million For Fibrosis Specialist | Chemical & Engineering News
Volume 92 Issue 19 | p. 17 | Concentrates
Issue Date: May 12, 2014

Shire To Pay $75 Million For Fibrosis Specialist

Department: Business
Keywords: rare disease, fibrosis

Irish drug company Shire will acquire Fibrotech, an Australian biopharmaceutical company, for $75 million. Fibrotech is developing a new class of drugs to treat health effects associated with fibrosis. The hook for Shire is Fibrotech’s lead product FT011, a therapy targeting focal segmental glomerulosclerosis (FSGS), currently in Phase I clinical trials. FSGS is a rare disease that affects the kidney’s filtering system and causes serious scarring.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment